Drug Discovery & Pharmaceuticals

RSS

Unique tiny Ilamas antibodies could be used for treatment of COVID-19

A unique type of tiny antibody produced by llamas could provide a new frontline treatment against Covid-19 that can be taken by patients as a simple nasal spray.

22 Sep 2021

Rice bioengineer receives $1.9 million NIH grant to improve time-release drugs

Time-released drugs are about to get a geometry lesson, thanks to bioengineers at Rice University.

21 Sep 2021

Researchers aim to develop edible plant-based mRNA vaccines

The future of vaccines may look more like eating a salad than getting a shot in the arm. UC Riverside scientists are studying whether they can turn edible plants like lettuce into mRNA vaccine factories.

16 Sep 2021

Grouping EGFR mutations provides an accurate way to match lung cancer patients to the right drugs

Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations by structure and function provide an accurate framework to match patients with non-small cell lung cancer (NSCLC) to the right drugs.

16 Sep 2021

MD Anderson and SNIPR BIOME join forces to advance new CRISPR-based microbiome therapeutics

The University of Texas MD Anderson Cancer Center and SNIPR BIOME today announced a strategic collaboration to advance new CRISPR-based microbiome therapeutics to reduce immune-related adverse events (irAE) in patients being treated with combined immune checkpoint inhibitors.

13 Sep 2021

Study identifies FDA-approved drugs that are effective in suppressing SARS-CoV-2 replication

Despite the development of SARS-CoV-2 vaccines, effective therapeutics are needed until worldwide immunity has been achieved.

10 Sep 2021

Researchers use amphibian foam to deliver drugs for the first time

Amphibian foam has been used in drug delivery for the first time by researchers, which could help to combat the rise of antimicrobial resistance.

9 Sep 2021

Newly identified mechanism can accelerate the development of STING-activating drugs using imaging

A new study from scientists at the UCLA Jonsson Comprehensive Cancer Center found that emerging drugs that activate the protein STING, a well-established regulator of immune cell activation, substantially alter the activity of metabolic pathways responsible for generating the nucleotide building blocks for DNA.

7 Sep 2021

Booster shot of Pfizer COVID-19 vaccine provides additional protection against SARS-CoV-2 infection

A team of scientists from the USA and Israel has recently highlighted the importance of a third booster dose of the Pfizer/BioNTech coronavirus disease 2019 (COVID-19) vaccine in achieving additional protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the medRxiv* preprint server.

2 Sep 2021

New candidate vaccine for COVID-19 found to be efficacious in preclinical models

More than a year after the start of the COVID-19 pandemic, several vaccines have been authorized thanks to unprecedented worldwide research efforts. These first-generation vaccines bring great hope and are a mainstay in fighting the virus.

1 Sep 2021

$1.3 million in NIH funding to enable drug delivery technology research

Two National Institute of Health grants totaling over $1.3 million will enable research into antibody-mediated drug delivery technology for the treatment of cancer and autoimmune disorders. L. Nathan Tumey, assistant professor of pharmaceutical sciences at Binghamton University, State University of New York, is the Principal Investigator on both grants -; $1.2 million from the National Institute of General Medical Sciences and $150,000 from the National Institute of Allergy and Infectious Diseases.

31 Aug 2021

New compounds offer a two-for-one punch to fight estrogen-sensitive breast cancer

A set of compounds developed by scientists at Scripps Research in Florida target estrogen-sensitive breast cancer cells in new ways, potentially creating better options for patients with treatment-resistant cancers.

31 Aug 2021

Aston University secures KTP project to assist Catalent in developing orally disintegrating tablets

Aston University researchers based in the College of Health and Life Sciences have been awarded a Knowledge Transfer Partnership (KTP) project by Innovate UK, to bring its academic and scientific expertise to assist Catalent in the development of its Zydis® technology, the leading orally disintegrating tablet (ODT).

27 Aug 2021

Study suggests a balanced approach to developing safer opioid analgesics

Opioids are powerful painkillers but their use is hindered because patients become tolerant to them, requiring higher and higher doses, and overdoses can cause respiratory depression and death.

24 Aug 2021

Peptoids could one day cure or prevent herpes, COVID-19

In addition to antibodies and white blood cells, the immune system deploys peptides to fight viruses and other pathogens.

24 Aug 2021

Heidelberg researchers focus on developing drugs against flavi- and coronaviruses

New drugs are intended to help stop viral zoonoses - infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation.

20 Aug 2021

Researchers create a novel strategy for developing an effective TB vaccine

Innovators at Purdue University and Houston Methodist Research Institute have created a novel strategy for developing an effective vaccine for a widespread form of tuberculosis.

20 Aug 2021

Scientists propose innovative method to test the effectiveness of coronavirus medicines

South Ural State University scientists have proposed an innovative method for testing the effectiveness of medicines for coronavirus. According to the researchers, it is necessary to focus on the maximum coincidence of the ligand and the receptor. The results of the work have been published in the highly-rated journal "Molecules"(Q1).

18 Aug 2021

Designing antimalarials with multiple targeting mechanisms of action

Malaria remains a serious global health threat. While the current discoveries of antimalarials are almost totally focused on single mode-of-action inhibitors, multi-targeting inhibitors are highly desired to overcome the increasingly serious drug resistance.